Point72 Asset Management Exits Position in Corvus Pharmaceuticals, Inc. (CRVS)

Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen have filed a Schedule 13G/A with the SEC, reporting that they have fully exited their position in Corvus Pharmaceuticals, Inc. (CRVS) as of March 31, 2026. This amendment (Amendment No. 1) indicates that the reporting persons no longer beneficially own any shares of the issuer's common stock, which previously represented a significant holding. The filing confirms that the reporting persons have ceased to be beneficial owners of more than five percent of the class of securities. The entities involved include the Delaware limited partnership Point72 Asset Management and its general partner, Point72 Capital Advisors, both of which are ultimately controlled by Steven A. Cohen. The filing was certified as not being made for the purpose of changing or influencing the control of the issuer. This exit marks a complete divestment by the Point72 group from Corvus Pharmaceuticals.